"Enalapril" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.
| Descriptor ID |
D004656
|
| MeSH Number(s) |
D12.644.456.345.360
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Enalapril".
Below are MeSH descriptors whose meaning is more specific than "Enalapril".
This graph shows the total number of publications written about "Enalapril" by people in this website by year, and whether "Enalapril" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 7 | 3 | 10 |
| 2018 | 7 | 6 | 13 |
| 2019 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Enalapril" by people in Profiles.
-
Effects of Renin-Angiotensin Inhibition on ACE2 (Angiotensin-Converting Enzyme 2) and TMPRSS2 (Transmembrane Protease Serine 2) Expression: Insights Into COVID-19. Hypertension. 2020 10; 76(4):e29-e30.
-
Facts and reflections on COVID-19 and anti-hypertensives drugs. Drug Discov Ther. 2020 May 06; 14(2):105-106.
-
Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. Eur Heart J. 2019 10 21; 40(40):3345-3352.
-
Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. Circulation. 2019 10 22; 140(17):1369-1379.
-
Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF. JACC Heart Fail. 2019 06; 7(6):457-465.
-
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 02 07; 380(6):539-548.
-
A pilot study exploring the impact of cardiac medications on ciliary beat frequency: possible implications for clinical management. J Basic Clin Physiol Pharmacol. 2018 09 25; 29(5):565-571.
-
Effects on 24-hour blood pressure variability of ace-inhibition and calcium channel blockade as monotherapy or in combination. Sci Rep. 2018 09 13; 8(1):13779.
-
Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study. Int J Cardiol. 2018 08 01; 264:118-123.
-
Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2018 06 01; 3(6):498-505.